Volker Schellenberger

Company: Amunix Pharmaceuticals Inc.

Job title: President & Chief Executive Officer

Seminars:

Mitigate Toxicity by Engineering & Assembling Novel Formats to Mitigate Toxicity 2:30 pm

Optimizing protein structure of BITEs to achieve increased selectivity of binding to tumor cells to minimize interactions with healthy tissue Navigating reducing affinity to reduce risk of CRS and toxicity, compared to decreased potency and risk reducing efficacy Explore the promise of tri- and multi-specific cell engagers for dual targetingRead more

day: Conference Day 1